Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, 2-treatment, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-229 and the Administration of AD-2291 for Healthy Adults in Fasting State

NCT07385248 is registered in ClinicalTrials.gov with Addpharma Inc. as lead sponsor.

NCT NCT07385248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07385248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, 2-treatment, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-229 and the Administration of AD-2291 for Healthy Adults in Fasting State
Lead sponsor
Addpharma Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
June 30, 2026
Enrollment
28 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastritis